Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy

Yu, Xueping; Wang, Xiupeng; Yamazaki, Atsushi; Li, Xia

doi:10.1039/d2tb00337f

Cited by 10 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global lung cancer occurrence could be due to outdoor ambient PM2.5 and tobacco (Guo et al, 2020;Turner et al, 2020;Frazer et al, 2022). Multiple gene mutations have been found in NSCLC patient, including epidermal growth factor receptor (EGFR) (Zhao D. et al, 2022;Castaneda-Gonzalez et al, 2022), Kirsten rat sarcoma viral oncogene homolog (KRAS) (Desage et al, 2022;Garcia-Robledo et al, 2022), anaplastic lymphoma kinase (ALK) (Cognigni et al, 2022;Xiang et al, 2022), Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) (Ni and Zhang, 2021;Vathiotis et al, 2021;Yu X. et al, 2022), B-Raf proto-oncogene (BRAF) (Abdayem and Planchard, 2022;Riudavets et al, 2022;Sforza et al, 2022), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), AKT serine/threonine kinase 1 (AKT1), mitogen-activated protein kinase kinase 1 (MAP2K1) (Kim and Giaccone, 2018;, c-ros oncogene 1 (ROS1) (Guaitoli et al, 2021;Yu Z. Q. et al, 2022), neurotrophic tyrosine receptor kinase (NTRK) (Liu C. et al, 2022;Qin and Patel, 2022), and mesenchymal-epithelial transition factor (MET) (Pao and Girard, 2011;Olmedo et al, 2022) (Figure 1). In SCLC patients, gene mutations often include retinoblastoma (Rb), TP53, PTEN, FBXW7, VHL mutations (Cardona et al, 2019;Guan et al, 2022).…”

Section: Publisher's Notementioning

confidence: 99%

Adaptive Immune Resistance in Cancer Therapy

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Section: Publisher's Notementioning

confidence: 99%

Adaptive Immune Resistance in Cancer Therapy

2024

Frontiers Research Topics

View full text Add to dashboard Cite

show abstract

“…Different concentrations (10,20, and 50 µg/mL) of MS-Cu nanoparticles were dispersed into a 25 mM NaHCO 3 buffer solution with methylene blue (MB, 10 µg/mL) and H 2 O 2 (10 mM). After the solutions were incubated at 37 • C for determined time points (0.5, 1, and 1.5 h), an ultraviolet-visible (UV-vis) absorption spectrometer was adopted to determine the absorbance of MB at 664 nm.…”

Section: Extracellular Ros Generation Induced By Ms-cu Nanoparticlesmentioning

confidence: 99%

“…Tumor microenvironment (TME) is usually characterized by mild acidity, hypoxia, and powerful antioxidative systems [15,16], which would strongly restrict the chemotherapy and immunotherapy efficacies [17][18][19][20]. The regulatory functions of MS-Cu nanoparticles in the tumor microenvironment remain unclear.…”

Section: Introductionmentioning

confidence: 99%

An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy

Yuan,

Wang

2023

Nanomaterials

Self Cite

View full text Add to dashboard Cite

Clinically, cancer chemotherapy still faces unsatisfactory efficacy due to drug resistance and severe side effects, including tiredness, hair loss, feeling sick, etc. The clinical benefits of checkpoint inhibitors have revived hope for cancer immunotherapy, but the objective response rate of immune checkpoint inhibitors remains around 10–40%. Herein, two types of copper-doped mesoporous silica nanoparticles (MS-Cu–1 with a diameter of about 30 nm and MS-Cu–2 with a diameter of about 200 nm) were synthesized using a one-pot method. Both MS-Cu–1 and MS-Cu–2 nanoparticles showed excellent tumor microenvironment regulation properties with elevated extracellular and intracellular ROS generation, extracellular and intracellular oxygenation, and intracellular GSH depletion. In particular, MS-Cu–2 nanoparticles demonstrated a better microenvironment modulation effect than MS-Cu–1 nanoparticles. The DSF/MS-Cu composites with disulfiram (DSF) and copper co-delivery characteristics were prepared by a straightforward method using chloroform as the solvent. Cell survival rate and live/dead staining results showed that DSF and MS-Cu alone were not toxic to LLC cells, while a low dose of DSF/MS-Cu (1–10 μg/mL) showed a strong cell-killing effect. In addition, MS-Cu–2 nanoparticles released more Cu2+ in a weakly acidic environment (pH = 5) than in a physiological environment (pH = 7.4), and the Cu2+ released was 41.72 ± 0.96 mg/L in 1 h under weakly acidic conditions. UV–visible absorption spectrometry confirmed the production of tumor-killing drugs (CuETs). The intratumoral injection of DSF/MS-Cu significantly inhibited tumor growth in vivo by converting nontoxic DSF/MS-Cu into toxic CuETs. The combination of DSF/MS-Cu and anti-CTLA–4 antibody further inhibited tumor growth, showing the synergistic effect of DSF/MS-Cu and immune checkpoint inhibitors.

show abstract

“…More importantly, while improving the specific degradation of MSNs, the metal ions also have therapeutic and diagnostic functions. For example, the reactive oxygen species (ROS), produced by doped metal ions such as Fe 3+ , Cu 2+ and Mn 4+ through Fenton or Fenton-like reaction, can be utilized for tumor treatment [17][18][19]. In addition to inducing tumor cell apoptosis through chemodynamic therapy (CDT), metal ions can induce tumor cell death through other means, for example, Fe 2+ causes lipid peroxidation in tumor cells, leading to the occurrence of ferroptosis [20], and Cu 2+ can disrupt the tricarboxylic acid cycle, resulting in the aggregation of lipoylated proteins and the loss of iron-sulfur clusters, which eventually leads to cuproptosis [21,22].…”

Section: Introductionmentioning

confidence: 99%

Biodegradable Ca2+ Doped Mesoporous Silica Nanoparticles Promote Chemotherapy Synergism with Calcicoptosis and Activate Anti-Tumor Immunity

Liu,

Tang,

Huang

2024

Inorganics

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSNs), an excellent carrier material, have been widely used in tumor therapy as a vector for numerous therapeutic substances to boost therapeutical efficiency and specificity, such as loading them with chemotherapy drugs to improve the efficacy of chemotherapy. Nevertheless, they still face hurdles, such as lack of specificity and poor efficacy of monotherapy. The construction of multifunctional MSNs with excellent therapeutic effects by introducing metal ions has attracted the attention of many researchers. Herein, we demonstrated a calcium doped, chemotherapy drug doxorubicin (Dox) loaded, specific degradation nanoplatform, prepared using the sol–gel method by introducing calcium ions into an MSN framework, which enabled the doped nanoplatform to enhance chemotherapy and activate anti-tumor immune response. As a proof of concept, the doping of Ca2+ endowed MSNs with excellent specific degradation and pH responsive drug release, and enabled the synergy of chemotherapy and calcicoptosis. Furthermore, this nanoplatform also effectively elicited immunogenic cell death (ICD) and promoted the maturation of dendritic cells (DCs), realizing the activation of the anti-tumor immune system. The Ca2+ doped MSNs (CMSNs), that can activate immune response with specific degradation capability, demonstrate a practical strategy for the effective synergy between chemotherapy and calcicoptosis, providing a new paradigm for promoting chemotherapy-related treatment.

show abstract

Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy

Abstract: Chemotherapy is one of the major clinical anticancer therapies. Whereas, its efficacy is limited by many factors, including the complex tumor microenvironment (TME). Herein, manganese-doped mesoporous silica nanoparticles (MM NPs)...

Cited by 10 publications

References 54 publications

Adaptive Immune Resistance in Cancer Therapy

Adaptive Immune Resistance in Cancer Therapy

An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy

Biodegradable Ca2+ Doped Mesoporous Silica Nanoparticles Promote Chemotherapy Synergism with Calcicoptosis and Activate Anti-Tumor Immunity

Contact Info

Product

Resources

About